Efficacy of Methotrexate Alone or With Low-Dose Prednisone in Alopecia Areata Totalis or Universalis
This randomized clinical trial evaluates the efficacy and tolerance of methotrexate alone or combined with low-dose prednisone in patients with chronic and recalcitrant alopecia areata totalis or universalis. (Source: JAMA Dermatology)
Source: JAMA Dermatology - March 8, 2023 Category: Dermatology Source Type: research
Overall and Racial and Ethnic Subgroup Prevalences of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis
This cross-sectional study examines the prevalence of alopecia areata, alopecia totalis, and alopecia universalis overall and among racial and ethnic groups in the US. (Source: JAMA Dermatology)
Source: JAMA Dermatology - March 1, 2023 Category: Dermatology Source Type: research
Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children
This cohort study examines the annual prevalence and incidence of alopecia areata and alopecia totalis/alopecia universalis in the US. (Source: JAMA Dermatology)
Source: JAMA Dermatology - March 1, 2023 Category: Dermatology Source Type: research
Cytokine Dysregulation in Alopecia Areata Associated with Atopy
Alopecia areata (AA) is a common autoimmune disease, causing patchy hair loss that can progress to involve the entire scalp (totalis) or body (universalis). Alopecia areata co- morbidities include atopic diseases with a high association approaching 25%. The specific immune mechanisms driving hair loss and association of AA and atopy may be related to specific systemic production of cytokines which was investigated in this study of patients with and without atopy. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Galina Tereshenko, Nikolay Potekaev, Aida Gadzhigoroeva, Olga Zhukova, Roman Khanferyan, Lawrence DuBuske Source Type: research
066 Incidence rates and prevalence of hospital-treated alopecia areata in Denmark (1995-2016)
Alopecia areata (AA) is an autoimmune disease that has an underlying immuno-inflammatory pathogenesis and is characterized by nonscarring hair loss ranging from small patches to complete scalp (alopecia totalis [AT]), face, and body hair loss (alopecia universalis [AU]). Studies describing the epidemiology of AA, especially measuring the occurrence of AA within the general population, are scarce. This was a historical population-based cohort study in Denmark that estimated incidence rate (IR) and prevalence of hospital-treated AA among persons 12 years or older. (Source: Journal of Investigative Dermatology)
Source: Journal of Investigative Dermatology - November 18, 2022 Category: Dermatology Authors: P. George, U. Heide-J ørgensen, O. Jagun, L. Napatalung, R. Wolk, S. Zwillich, V. Ehrenstein Source Type: research
Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
J Autoimmun. 2022 Nov 3;133:102926. doi: 10.1016/j.jaut.2022.102926. Online ahead of print.ABSTRACTAlopecia Areata (AA) is a T-cell mediated autoimmune attack on hair follicles resulting in rapidly developing areas of hair loss involving the scalp and beard that can progress to total scalp hair loss (alopecia totalis) and loss of eyebrows, eyelashes, and total body hair (alopecia universalis). Affected patients have high rates of psychological disorders and decreased quality of life. There are no FDA approved treatments, and the available treatments have a high failure rate. JAK inhibitors are remarkably effective in many ...
Source: Journal of Autoimmunity - November 6, 2022 Category: Allergy & Immunology Authors: Isabelle Paggioli Jeremy Moss Source Type: research
